Corporate

You heard it here first.

 
 
 

Our news

Bringing you the latest!

Corporate

Clinical trial conducted by MedinCell confirms the safety of continuous administration of ivermectin

Corporate

19 April 2021

Covid-19: MedinCell presents positive first results from the clinical trial aiming at validating the safety of continuous administration of Ivermectin

Corporate - Investors

17 December 2020

First long-acting injectable (LAI) antipsychotic using MedinCell’s technology reaches Phase 3 clinical study primary completion date

Corporate

12 November 2020

 
 

CONTACT

  • This field is for validation purposes and should be left unchanged.